This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-199a-5p | A2ML1 | -0.36 | 0.04351 | -1.64 | 0.00028 | miRanda | -0.44 | 7.0E-5 | NA | |
2 | hsa-miR-199a-5p | ABCA13 | -0.36 | 0.04351 | 0.72 | 0.08476 | miRanda | -0.2 | 0.04305 | NA | |
3 | hsa-miR-199a-5p | ABI1 | -0.36 | 0.04351 | -0.24 | 0.0098 | miRanda | -0.12 | 0 | NA | |
4 | hsa-miR-148a-5p | ABL2 | -1 | 0 | 1.1 | 0 | miRNATAP | -0.11 | 9.0E-5 | NA | |
5 | hsa-miR-30a-5p | ABL2 | -1.8 | 0 | 1.1 | 0 | mirMAP; miRNATAP | -0.18 | 0 | NA | |
6 | hsa-miR-30a-5p | ACAP2 | -1.8 | 0 | 0.11 | 0.40427 | MirTarget; miRNATAP | -0.1 | 0.00116 | NA | |
7 | hsa-miR-199a-5p | ACER2 | -0.36 | 0.04351 | -0.24 | 0.26552 | miRanda | -0.23 | 2.0E-5 | NA | |
8 | hsa-miR-199a-5p | ACOT11 | -0.36 | 0.04351 | -0.47 | 0.01215 | mirMAP | -0.14 | 0.00269 | NA | |
9 | hsa-miR-30a-5p | ACTN1 | -1.8 | 0 | 0.8 | 0 | miRNATAP | -0.23 | 0 | NA | |
10 | hsa-miR-148a-5p | ACTR1A | -1 | 0 | -0.07 | 0.3734 | miRNAWalker2 validate | -0.11 | 0 | NA | |
11 | hsa-miR-30a-5p | ACVR1 | -1.8 | 0 | 0.7 | 0 | MirTarget; miRNATAP | -0.18 | 0 | NA | |
12 | hsa-miR-155-5p | ACVR2A | 0.53 | 0.00249 | -0.89 | 0 | miRNATAP | -0.11 | 0.00016 | NA | |
13 | hsa-miR-193b-5p | ACVR2A | 1.1 | 0 | -0.89 | 0 | MirTarget | -0.31 | 0 | NA | |
14 | hsa-miR-155-5p | ADAM10 | 0.53 | 0.00249 | 0.48 | 0.00248 | miRNAWalker2 validate | -0.15 | 0.00015 | NA | |
15 | hsa-miR-193b-5p | ADAM22 | 1.1 | 0 | -0.46 | 0.16333 | MirTarget | -0.7 | 0 | NA | |
16 | hsa-miR-30a-5p | ADAMTS6 | -1.8 | 0 | 2.34 | 0 | MirTarget; miRNATAP | -0.17 | 0.00471 | NA | |
17 | hsa-miR-193b-5p | ADHFE1 | 1.1 | 0 | -2 | 0 | MirTarget | -0.36 | 0 | NA | |
18 | hsa-miR-199a-5p | ADK | -0.36 | 0.04351 | 0.22 | 0.03771 | miRanda | -0.11 | 1.0E-5 | NA | |
19 | hsa-miR-199a-5p | ADNP2 | -0.36 | 0.04351 | -0.05 | 0.62164 | miRanda | -0.12 | 0 | NA | |
20 | hsa-miR-30a-5p | AFAP1L2 | -1.8 | 0 | 1.01 | 0 | MirTarget; miRNATAP | -0.22 | 0 | NA | |
21 | hsa-miR-148a-5p | AGPAT4 | -1 | 0 | 0.57 | 0.00219 | mirMAP | -0.3 | 0 | NA | |
22 | hsa-miR-199a-5p | AGPAT5 | -0.36 | 0.04351 | -0.05 | 0.6317 | miRanda | -0.12 | 2.0E-5 | NA | |
23 | hsa-miR-155-5p | AGTR1 | 0.53 | 0.00249 | -1.69 | 0 | miRNAWalker2 validate; miRTarBase | -0.37 | 2.0E-5 | 22525818 | MicroRNA-155 miR-155 is one of the micro RNAs miRNA most consistently involved in neoplastic diseases and it is known to repress the angiotensin II type 1 receptor AGTR1; The aim of the present study was to evaluate the expressions of miR-155 and AGTR1 and to clarify the potential efficacy of anti-miR-155 alone and in combination with AGTR1 blocker losartan in endometrial cancers; Expressions of miR-155 and AGTR1 were evaluated using real-time PCR and immunohistochemistry; miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues; We checked that abolishing the function of miR-155 and AGTR1 by anti-miR-155 or losartan inhibited cell survival of endometrial carcinoma cells respectively and furthermore combined treatment showed synergistic effects; In this study we characterized the expressions of miR-155 and AGTR1 in endometrial tissues; The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer |
24 | hsa-miR-155-5p | AHCYL2 | 0.53 | 0.00249 | -0.77 | 0 | miRNATAP | -0.11 | 0.00098 | NA | |
25 | hsa-miR-30a-5p | AHNAK | -1.8 | 0 | -0.84 | 0 | miRNATAP | -0.1 | 0.00711 | NA | |
26 | hsa-miR-193b-5p | AIF1L | 1.1 | 0 | -2.25 | 0 | MirTarget | -0.15 | 0.01876 | NA | |
27 | hsa-miR-193b-5p | AK3 | 1.1 | 0 | -0.85 | 0 | MirTarget | -0.13 | 2.0E-5 | NA | |
28 | hsa-miR-199a-5p | AKNA | -0.36 | 0.04351 | 0.23 | 0.10999 | miRanda | -0.1 | 0.00391 | NA | |
29 | hsa-miR-148a-5p | AKR1C1 | -1 | 0 | 0.01 | 0.97742 | mirMAP | -0.2 | 0.02663 | NA | |
30 | hsa-miR-30a-5p | AKR1C1 | -1.8 | 0 | 0.01 | 0.97742 | mirMAP | -0.39 | 7.0E-5 | NA | |
31 | hsa-miR-155-5p | AKR1C3 | 0.53 | 0.00249 | 0.34 | 0.34929 | miRNAWalker2 validate | -0.66 | 0 | NA | |
32 | hsa-miR-30a-5p | AMMECR1 | -1.8 | 0 | 0.41 | 0.0038 | miRNATAP | -0.29 | 0 | NA | |
33 | hsa-miR-199a-5p | AMPD3 | -0.36 | 0.04351 | 0.07 | 0.62369 | miRanda | -0.18 | 0 | NA | |
34 | hsa-miR-148a-5p | ANGPT2 | -1 | 0 | 1.61 | 0 | mirMAP | -0.11 | 0.00532 | NA | |
35 | hsa-miR-199a-5p | ANKFY1 | -0.36 | 0.04351 | 0.12 | 0.13381 | miRanda | -0.1 | 0 | NA | |
36 | hsa-miR-155-5p | ANKH | 0.53 | 0.00249 | 0.04 | 0.80588 | mirMAP | -0.13 | 0.00035 | NA | |
37 | hsa-miR-199a-5p | ANKRD22 | -0.36 | 0.04351 | -0.93 | 0.00017 | miRanda | -0.2 | 0.00065 | NA | |
38 | hsa-miR-199a-5p | ANKRD34B | -0.36 | 0.04351 | 1.37 | 0.00079 | miRanda | -0.21 | 0.03592 | NA | |
39 | hsa-miR-199a-5p | ANKRD36B | -0.36 | 0.04351 | 0.48 | 0.00714 | miRanda | -0.12 | 0.00664 | NA | |
40 | hsa-miR-155-5p | ANO5 | 0.53 | 0.00249 | -3.22 | 0 | MirTarget | -0.25 | 0.0205 | NA | |
41 | hsa-miR-155-5p | ANTXR1 | 0.53 | 0.00249 | 0.37 | 0.02991 | miRNAWalker2 validate | -0.14 | 0.00056 | NA | |
42 | hsa-miR-155-5p | AP1G1 | 0.53 | 0.00249 | -0.25 | 0.00213 | miRNAWalker2 validate | -0.11 | 0 | NA | |
43 | hsa-miR-30a-5p | AP4E1 | -1.8 | 0 | 0.02 | 0.81319 | miRNATAP | -0.12 | 0 | NA | |
44 | hsa-miR-30a-5p | APBB2 | -1.8 | 0 | 0.87 | 0 | mirMAP | -0.13 | 0.00026 | NA | |
45 | hsa-miR-199a-5p | APOL1 | -0.36 | 0.04351 | 1.76 | 0 | miRanda | -0.22 | 0.00018 | NA | |
46 | hsa-miR-199a-5p | APOL6 | -0.36 | 0.04351 | 0.12 | 0.50637 | miRanda | -0.22 | 0 | NA | |
47 | hsa-miR-155-5p | AR | 0.53 | 0.00249 | -3.13 | 0 | mirMAP | -0.19 | 0.04268 | NA | |
48 | hsa-miR-145-5p | ARAP2 | -0.47 | 0.00069 | -0.12 | 0.4455 | MirTarget | -0.18 | 0.00017 | NA | |
49 | hsa-miR-145-5p | ARF6 | -0.47 | 0.00069 | -0.43 | 0 | MirTarget | -0.1 | 0.0004 | 25253741 | lincRNA RoR and miR 145 regulate invasion in triple negative breast cancer via targeting ARF6 |
50 | hsa-miR-199a-5p | ARF6 | -0.36 | 0.04351 | -0.43 | 0 | MirTarget; PITA; miRanda; miRNATAP | -0.1 | 0 | NA | |
51 | hsa-miR-193b-5p | ARHGAP26 | 1.1 | 0 | -0.65 | 0.00029 | mirMAP | -0.44 | 0 | NA | |
52 | hsa-miR-155-5p | ARHGAP32 | 0.53 | 0.00249 | -0.97 | 0 | mirMAP | -0.18 | 0 | NA | |
53 | hsa-miR-155-5p | ARHGAP5 | 0.53 | 0.00249 | -0.43 | 0.00026 | mirMAP | -0.13 | 0 | NA | |
54 | hsa-miR-199a-5p | ARID3B | -0.36 | 0.04351 | 0.32 | 0.006 | miRanda | -0.12 | 1.0E-5 | NA | |
55 | hsa-miR-155-5p | ARL10 | 0.53 | 0.00249 | 0.03 | 0.88663 | miRNAWalker2 validate | -0.12 | 0.01005 | NA | |
56 | hsa-miR-155-5p | ARL15 | 0.53 | 0.00249 | -0.21 | 0.17368 | miRNAWalker2 validate; miRNATAP | -0.1 | 0.00608 | NA | |
57 | hsa-miR-155-5p | ARL2BP | 0.53 | 0.00249 | 0.14 | 0.06649 | MirTarget | -0.11 | 0 | NA | |
58 | hsa-miR-145-5p | ARL5B | -0.47 | 0.00069 | -0.22 | 0.1625 | MirTarget | -0.13 | 0.00985 | NA | |
59 | hsa-miR-199a-5p | ARL6IP1 | -0.36 | 0.04351 | 0.55 | 0 | miRanda | -0.12 | 0 | NA | |
60 | hsa-miR-30a-5p | ARRDC4 | -1.8 | 0 | 0.56 | 0.0027 | mirMAP | -0.26 | 0 | NA | |
61 | hsa-miR-30a-5p | ASAP1 | -1.8 | 0 | 0.94 | 0 | miRNATAP | -0.2 | 0 | NA | |
62 | hsa-miR-30a-5p | ASCC3 | -1.8 | 0 | 0.14 | 0.20099 | miRNAWalker2 validate; MirTarget | -0.11 | 3.0E-5 | NA | |
63 | hsa-miR-155-5p | ASNS | 0.53 | 0.00249 | 0.75 | 0 | miRNAWalker2 validate | -0.1 | 0.00685 | NA | |
64 | hsa-miR-155-5p | ASPH | 0.53 | 0.00249 | 0.03 | 0.80132 | miRNAWalker2 validate | -0.12 | 0.00011 | NA | |
65 | hsa-miR-30a-5p | ATF2 | -1.8 | 0 | 0.1 | 0.47373 | mirMAP | -0.12 | 0.0008 | NA | |
66 | hsa-miR-155-5p | ATF7 | 0.53 | 0.00249 | -0.28 | 0.00178 | mirMAP | -0.1 | 0 | NA | |
67 | hsa-miR-30a-5p | ATL3 | -1.8 | 0 | 0.29 | 0.02783 | mirMAP | -0.2 | 0 | NA | |
68 | hsa-miR-199a-5p | ATP10B | -0.36 | 0.04351 | -1.99 | 0 | miRanda | -0.26 | 0.00292 | NA | |
69 | hsa-miR-155-5p | ATP2B1 | 0.53 | 0.00249 | 0.59 | 1.0E-5 | miRNATAP | -0.16 | 0 | NA | |
70 | hsa-miR-30a-5p | ATP2B1 | -1.8 | 0 | 0.59 | 1.0E-5 | MirTarget; mirMAP; miRNATAP | -0.14 | 1.0E-5 | NA | |
71 | hsa-miR-30a-5p | ATP6V1C1 | -1.8 | 0 | 0.79 | 0 | miRNAWalker2 validate | -0.14 | 0 | NA | |
72 | hsa-miR-155-5p | ATRNL1 | 0.53 | 0.00249 | -1.25 | 0.00065 | MirTarget; mirMAP | -0.35 | 9.0E-5 | NA | |
73 | hsa-miR-155-5p | ATXN1L | 0.53 | 0.00249 | 0.02 | 0.81815 | miRNATAP | -0.12 | 1.0E-5 | NA | |
74 | hsa-miR-30a-5p | AVL9 | -1.8 | 0 | 0.23 | 0.01535 | MirTarget; mirMAP; miRNATAP | -0.19 | 0 | NA | |
75 | hsa-miR-199a-5p | B3GNT3 | -0.36 | 0.04351 | -0.55 | 0.04778 | miRanda | -0.37 | 0 | NA | |
76 | hsa-miR-30a-5p | B3GNT5 | -1.8 | 0 | 0.31 | 0.05343 | MirTarget; miRNATAP | -0.33 | 0 | NA | |
77 | hsa-miR-199a-5p | BACH1 | -0.36 | 0.04351 | 0.02 | 0.88442 | miRanda | -0.16 | 0 | NA | |
78 | hsa-miR-30a-5p | BACH1 | -1.8 | 0 | 0.02 | 0.88442 | miRNATAP | -0.17 | 0 | NA | |
79 | hsa-miR-30a-5p | BAG4 | -1.8 | 0 | 0.1 | 0.55198 | mirMAP | -0.13 | 0.00147 | NA | |
80 | hsa-miR-155-5p | BAG5 | 0.53 | 0.00249 | -0.33 | 0 | miRNAWalker2 validate | -0.11 | 0 | NA | |
81 | hsa-miR-30a-5p | BCL11B | -1.8 | 0 | 0.6 | 0.00031 | miRNATAP | -0.32 | 0 | NA | |
82 | hsa-miR-155-5p | BCL6 | 0.53 | 0.00249 | -0.43 | 0.00039 | miRNAWalker2 validate; miRTarBase | -0.15 | 0 | 23169640 | We show that Bcl6 is indirectly regulated by miR-155 through Mxd1/Mad1 up-regulation; Interestingly we found that miR-155 directly targets HDAC4 a corepressor partner of BCL6; Meta-analysis of the diffuse large B-cell lymphoma patient microarray data showed that miR-155 expression is inversely correlated with Bcl6 and Hdac4; Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias |
83 | hsa-miR-155-5p | BCORL1 | 0.53 | 0.00249 | 0.35 | 0.0045 | MirTarget | -0.21 | 0 | NA | |
84 | hsa-miR-155-5p | BDNF | 0.53 | 0.00249 | 0.04 | 0.88345 | miRNATAP | -0.23 | 0.00094 | NA | |
85 | hsa-miR-193b-5p | BEND7 | 1.1 | 0 | -1.93 | 0 | mirMAP | -0.59 | 0 | NA | |
86 | hsa-miR-148a-5p | BICD1 | -1 | 0 | 1.53 | 0 | mirMAP | -0.11 | 0.00714 | NA | |
87 | hsa-miR-30a-5p | BICD1 | -1.8 | 0 | 1.53 | 0 | mirMAP | -0.25 | 0 | NA | |
88 | hsa-miR-148a-5p | BICD2 | -1 | 0 | 0.46 | 0.00054 | mirMAP | -0.12 | 0.0001 | NA | |
89 | hsa-miR-199a-5p | BLK | -0.36 | 0.04351 | 0.52 | 0.18133 | miRanda | -0.19 | 0.04566 | NA | |
90 | hsa-miR-30a-5p | BNC1 | -1.8 | 0 | 1.78 | 0 | MirTarget; miRNATAP | -0.67 | 0 | NA | |
91 | hsa-miR-155-5p | BOC | 0.53 | 0.00249 | -2.04 | 0 | MirTarget | -0.11 | 0.03831 | NA | |
92 | hsa-miR-199a-5p | BRCA1 | -0.36 | 0.04351 | 1.08 | 0 | miRanda | -0.21 | 0 | NA | |
93 | hsa-miR-155-5p | BRD1 | 0.53 | 0.00249 | -0.19 | 0.01331 | MirTarget | -0.1 | 0 | NA | |
94 | hsa-miR-155-5p | BRWD3 | 0.53 | 0.00249 | -0.21 | 0.20442 | miRNATAP | -0.12 | 0.00358 | NA | |
95 | hsa-miR-30a-5p | BRWD3 | -1.8 | 0 | -0.21 | 0.20442 | MirTarget; miRNATAP | -0.12 | 0.00336 | NA | |
96 | hsa-miR-143-5p | BSPRY | 0.5 | 0.00432 | -2.1 | 0 | MirTarget | -0.32 | 2.0E-5 | NA | |
97 | hsa-miR-199a-5p | BSPRY | -0.36 | 0.04351 | -2.1 | 0 | miRanda | -0.3 | 3.0E-5 | NA | |
98 | hsa-miR-30a-5p | BTBD7 | -1.8 | 0 | -0 | 0.98244 | miRNATAP | -0.14 | 0 | NA | |
99 | hsa-miR-139-5p | BUB1 | -1.46 | 0 | 1.79 | 0 | miRanda | -0.29 | 0 | NA | |
100 | hsa-miR-199a-5p | BUB1 | -0.36 | 0.04351 | 1.79 | 0 | miRanda | -0.19 | 0 | NA | |
101 | hsa-miR-199b-5p | BUB1 | -1.08 | 0 | 1.79 | 0 | miRanda | -0.23 | 0 | NA | |
102 | hsa-miR-495-3p | BUB1 | -1.48 | 0 | 1.79 | 0 | MirTarget | -0.2 | 0 | NA | |
103 | hsa-miR-653-5p | BUB1 | -1.05 | 0 | 1.79 | 0 | MirTarget | -0.2 | 0 | NA | |
104 | hsa-miR-155-5p | C16orf87 | 0.53 | 0.00249 | 0.37 | 0.00013 | mirMAP | -0.1 | 2.0E-5 | NA | |
105 | hsa-miR-30a-5p | C16orf87 | -1.8 | 0 | 0.37 | 0.00013 | miRNATAP | -0.11 | 0 | NA | |
106 | hsa-miR-30a-5p | C6orf132 | -1.8 | 0 | -1.12 | 0 | mirMAP | -0.11 | 0.00988 | NA | |
107 | hsa-miR-30a-5p | C7orf43 | -1.8 | 0 | 0.38 | 0 | miRNATAP | -0.11 | 0 | NA | |
108 | hsa-miR-148a-5p | CA12 | -1 | 0 | 0.07 | 0.78271 | MirTarget | -0.23 | 2.0E-5 | NA | |
109 | hsa-miR-199a-5p | CALB1 | -0.36 | 0.04351 | 4.4 | 0 | miRanda | -0.35 | 0.02193 | NA | |
110 | hsa-miR-30a-5p | CALB2 | -1.8 | 0 | -0.4 | 0.25774 | miRNATAP | -0.26 | 0.00238 | NA | |
111 | hsa-miR-155-5p | CALU | 0.53 | 0.00249 | 0.94 | 0 | miRNAWalker2 validate | -0.18 | 0 | NA | |
112 | hsa-miR-30a-5p | CALU | -1.8 | 0 | 0.94 | 0 | MirTarget | -0.1 | 0.00116 | NA | |
113 | hsa-miR-30a-5p | CAND1 | -1.8 | 0 | 0.35 | 0.00016 | mirMAP | -0.14 | 0 | NA | |
114 | hsa-miR-30a-5p | CAPZA1 | -1.8 | 0 | 0.23 | 0.01273 | MirTarget; miRNATAP | -0.13 | 0 | NA | |
115 | hsa-miR-155-5p | CARD10 | 0.53 | 0.00249 | 0.62 | 0.0007 | MirTarget | -0.12 | 0.00644 | NA | |
116 | hsa-miR-145-5p | CASP10 | -0.47 | 0.00069 | 0.04 | 0.78895 | mirMAP | -0.21 | 0 | NA | |
117 | hsa-miR-199a-5p | CASP4 | -0.36 | 0.04351 | -0.17 | 0.26799 | miRanda | -0.13 | 0.0003 | NA | |
118 | hsa-miR-193b-5p | CBFA2T2 | 1.1 | 0 | 0.2 | 0.05841 | mirMAP | -0.16 | 0 | NA | |
119 | hsa-miR-193b-5p | CBFA2T3 | 1.1 | 0 | -0.34 | 0.08121 | mirMAP | -0.18 | 0.00029 | NA | |
120 | hsa-miR-199a-5p | CBL | -0.36 | 0.04351 | 0.36 | 0.00252 | MirTarget; PITA; miRNATAP | -0.12 | 4.0E-5 | NA | |
121 | hsa-miR-30a-5p | CBLB | -1.8 | 0 | 1 | 0 | MirTarget | -0.15 | 0 | NA | |
122 | hsa-miR-30a-5p | CBX2 | -1.8 | 0 | 1.48 | 0 | miRNATAP | -0.33 | 0 | NA | |
123 | hsa-miR-199a-5p | CCDC15 | -0.36 | 0.04351 | 0.19 | 0.08531 | miRanda | -0.16 | 0 | NA | |
124 | hsa-miR-199a-5p | CCDC88C | -0.36 | 0.04351 | 0.11 | 0.42319 | PITA; miRanda; miRNATAP | -0.11 | 0.00094 | NA | |
125 | hsa-miR-33a-5p | CCL5 | 1.13 | 0 | 1.31 | 0 | MirTarget | -0.23 | 1.0E-5 | NA | |
126 | hsa-miR-30a-5p | CCNA1 | -1.8 | 0 | 1.54 | 0.00197 | MirTarget | -0.48 | 9.0E-5 | NA | |
127 | hsa-miR-199a-5p | CCNA2 | -0.36 | 0.04351 | 1.57 | 0 | miRanda | -0.21 | 0 | NA | |
128 | hsa-miR-155-5p | CCND1 | 0.53 | 0.00249 | -0.01 | 0.95947 | miRNAWalker2 validate | -0.21 | 0.0001 | 26955820 | MicroRNA 155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1 |
129 | hsa-miR-30a-5p | CCNE2 | -1.8 | 0 | 1.24 | 0 | miRNATAP | -0.16 | 5.0E-5 | NA | |
130 | hsa-miR-148a-5p | CD109 | -1 | 0 | 1.07 | 0 | mirMAP | -0.11 | 0.00343 | NA | |
131 | hsa-miR-155-5p | CD109 | 0.53 | 0.00249 | 1.07 | 0 | miRNAWalker2 validate | -0.18 | 0 | NA | |
132 | hsa-miR-155-5p | CD36 | 0.53 | 0.00249 | -1.17 | 4.0E-5 | miRNAWalker2 validate | -0.33 | 0 | NA | |
133 | hsa-miR-148a-5p | CD44 | -1 | 0 | 0.51 | 7.0E-5 | mirMAP | -0.12 | 8.0E-5 | 23861222 | In MHCC97H and MHCC97L cells over-expression of miR-148a blocked the EMT process attenuated the expression of CD90 and CD44 biomarkers for liver cancer stem cells and inhibited their migratory capacity |
134 | hsa-miR-30a-5p | CD44 | -1.8 | 0 | 0.51 | 7.0E-5 | miRNAWalker2 validate | -0.23 | 0 | NA | |
135 | hsa-miR-145-5p | CD47 | -0.47 | 0.00069 | 0.43 | 0.00075 | miRNATAP | -0.15 | 0.00016 | NA | |
136 | hsa-miR-30a-5p | CDC20 | -1.8 | 0 | 1.92 | 0 | miRNAWalker2 validate | -0.27 | 0 | NA | |
137 | hsa-miR-155-5p | CDC42BPB | 0.53 | 0.00249 | 0.05 | 0.6247 | miRNAWalker2 validate | -0.17 | 0 | NA | |
138 | hsa-miR-199a-5p | CDC6 | -0.36 | 0.04351 | 1.92 | 0 | miRanda | -0.17 | 0 | NA | |
139 | hsa-miR-199a-5p | CDC7 | -0.36 | 0.04351 | 1.03 | 0 | MirTarget; miRanda | -0.17 | 0 | NA | |
140 | hsa-miR-30a-5p | CDCP1 | -1.8 | 0 | 0.18 | 0.22385 | miRNAWalker2 validate | -0.23 | 0 | NA | |
141 | hsa-miR-199a-5p | CDH1 | -0.36 | 0.04351 | -0.13 | 0.4686 | MirTarget; miRanda | -0.18 | 2.0E-5 | 25080937 | In contrast inhibition of miR-199a-5p impaired the metastatic potential of GC cells in vitro and in vivo and E-cadherin was identified as a direct and functional target of miR-199a-5p in GC cells |
142 | hsa-miR-155-5p | CDH13 | 0.53 | 0.00249 | 0.42 | 0.06126 | miRNAWalker2 validate | -0.33 | 0 | NA | |
143 | hsa-miR-30a-5p | CDK12 | -1.8 | 0 | 0.31 | 0.00076 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
144 | hsa-miR-148a-5p | CDK6 | -1 | 0 | 0.94 | 0 | mirMAP | -0.17 | 6.0E-5 | NA | |
145 | hsa-miR-30a-5p | CDK6 | -1.8 | 0 | 0.94 | 0 | mirMAP | -0.24 | 0 | NA | |
146 | hsa-miR-155-5p | CDS1 | 0.53 | 0.00249 | -0.63 | 0 | miRNATAP | -0.13 | 5.0E-5 | NA | |
147 | hsa-miR-193b-5p | CEACAM5 | 1.1 | 0 | -3.14 | 0 | MirTarget | -0.93 | 0 | NA | |
148 | hsa-miR-30a-5p | CELSR3 | -1.8 | 0 | 2.18 | 0 | MirTarget; miRNATAP | -0.28 | 1.0E-5 | NA | |
149 | hsa-miR-199a-5p | CENPA | -0.36 | 0.04351 | 2.21 | 0 | miRanda | -0.15 | 0.00021 | NA | |
150 | hsa-miR-139-5p | CENPF | -1.46 | 0 | 1.74 | 0 | miRanda | -0.31 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | INTRACELLULAR SIGNAL TRANSDUCTION | 143 | 1572 | 1.892e-13 | 8.804e-10 |
2 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 120 | 1275 | 2.331e-12 | 2.711e-09 |
3 | REGULATION OF CELL PROLIFERATION | 135 | 1496 | 1.805e-12 | 2.711e-09 |
4 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 154 | 1784 | 1.352e-12 | 2.711e-09 |
5 | NEUROGENESIS | 128 | 1402 | 3.322e-12 | 3.091e-09 |
6 | TISSUE DEVELOPMENT | 135 | 1518 | 5.169e-12 | 4.009e-09 |
7 | POSITIVE REGULATION OF GENE EXPRESSION | 147 | 1733 | 1.795e-11 | 1.089e-08 |
8 | CELL PROLIFERATION | 75 | 672 | 2.018e-11 | 1.089e-08 |
9 | PHOSPHORYLATION | 114 | 1228 | 2.106e-11 | 1.089e-08 |
10 | LOCOMOTION | 106 | 1114 | 2.701e-11 | 1.257e-08 |
11 | POSITIVE REGULATION OF CELL PROLIFERATION | 84 | 814 | 6.985e-11 | 2.955e-08 |
12 | PROTEIN PHOSPHORYLATION | 92 | 944 | 1.784e-10 | 6.917e-08 |
13 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 79 | 771 | 3.724e-10 | 1.238e-07 |
14 | CELL DEVELOPMENT | 123 | 1426 | 3.673e-10 | 1.238e-07 |
15 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 157 | 1977 | 4.794e-10 | 1.487e-07 |
16 | REGULATION OF CELL DIFFERENTIATION | 126 | 1492 | 8.269e-10 | 2.405e-07 |
17 | EPITHELIUM DEVELOPMENT | 90 | 945 | 9.234e-10 | 2.527e-07 |
18 | CELL CYCLE PROCESS | 99 | 1081 | 1.044e-09 | 2.698e-07 |
19 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 147 | 1848 | 1.713e-09 | 4.194e-07 |
20 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 102 | 1142 | 2.212e-09 | 5.147e-07 |
21 | REGULATION OF CELL DEATH | 123 | 1472 | 2.568e-09 | 5.69e-07 |
22 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 134 | 1656 | 3.512e-09 | 7.428e-07 |
23 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 92 | 1004 | 4.15e-09 | 8.396e-07 |
24 | CELL CYCLE | 112 | 1316 | 5.27e-09 | 1.022e-06 |
25 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 39 | 285 | 6.314e-09 | 1.175e-06 |
26 | MITOTIC CELL CYCLE | 75 | 766 | 7.782e-09 | 1.393e-06 |
27 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 130 | 1618 | 9.599e-09 | 1.654e-06 |
28 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 91 | 1008 | 1.045e-08 | 1.737e-06 |
29 | CYTOSKELETON ORGANIZATION | 79 | 838 | 1.635e-08 | 2.624e-06 |
30 | NEGATIVE REGULATION OF CELL DEATH | 81 | 872 | 2.053e-08 | 3.185e-06 |
31 | ACTIN FILAMENT BASED PROCESS | 51 | 450 | 2.184e-08 | 3.218e-06 |
32 | PROTEIN LOCALIZATION | 140 | 1805 | 2.213e-08 | 3.218e-06 |
33 | CELL MOTILITY | 78 | 835 | 2.996e-08 | 4.1e-06 |
34 | LOCALIZATION OF CELL | 78 | 835 | 2.996e-08 | 4.1e-06 |
35 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 139 | 1805 | 3.886e-08 | 5.167e-06 |
36 | HEAD DEVELOPMENT | 69 | 709 | 4.013e-08 | 5.187e-06 |
37 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 71 | 740 | 4.481e-08 | 5.635e-06 |
38 | EMBRYO DEVELOPMENT | 81 | 894 | 6.062e-08 | 7.423e-06 |
39 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 85 | 957 | 6.808e-08 | 7.919e-06 |
40 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 130 | 1672 | 6.643e-08 | 7.919e-06 |
41 | REGULATION OF PROTEIN MODIFICATION PROCESS | 132 | 1710 | 7.874e-08 | 8.723e-06 |
42 | EPITHELIAL CELL DIFFERENTIATION | 53 | 495 | 7.712e-08 | 8.723e-06 |
43 | REGULATION OF HYDROLASE ACTIVITY | 108 | 1327 | 1.046e-07 | 1.132e-05 |
44 | REGULATION OF CELL ADHESION | 62 | 629 | 1.269e-07 | 1.342e-05 |
45 | NEGATIVE REGULATION OF CELL COMMUNICATION | 99 | 1192 | 1.443e-07 | 1.492e-05 |
46 | TISSUE MORPHOGENESIS | 55 | 533 | 1.501e-07 | 1.519e-05 |
47 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 109 | 1360 | 1.969e-07 | 1.949e-05 |
48 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 111 | 1395 | 2.168e-07 | 2.101e-05 |
49 | CELL JUNCTION ORGANIZATION | 27 | 185 | 3.649e-07 | 3.372e-05 |
50 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 134 | 1791 | 3.696e-07 | 3.372e-05 |
51 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 77 | 872 | 3.665e-07 | 3.372e-05 |
52 | RESPONSE TO ENDOGENOUS STIMULUS | 113 | 1450 | 4.767e-07 | 4.266e-05 |
53 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 117 | 1517 | 4.967e-07 | 4.361e-05 |
54 | CELL DIVISION | 48 | 460 | 6.747e-07 | 5.606e-05 |
55 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 64 | 689 | 6.598e-07 | 5.606e-05 |
56 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 40 | 352 | 6.738e-07 | 5.606e-05 |
57 | NEURON DIFFERENTIATION | 76 | 874 | 7.93e-07 | 6.474e-05 |
58 | CELL CYCLE CHECKPOINT | 27 | 194 | 9.518e-07 | 7.636e-05 |
59 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 140 | 1929 | 1.095e-06 | 8.493e-05 |
60 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 28 | 207 | 1.079e-06 | 8.493e-05 |
61 | NEGATIVE REGULATION OF GENE EXPRESSION | 114 | 1493 | 1.157e-06 | 8.585e-05 |
62 | MORPHOGENESIS OF AN EPITHELIUM | 43 | 400 | 1.17e-06 | 8.585e-05 |
63 | REGULATION OF CELL SUBSTRATE ADHESION | 25 | 173 | 1.181e-06 | 8.585e-05 |
64 | REGULATION OF CELL DEVELOPMENT | 73 | 836 | 1.13e-06 | 8.585e-05 |
65 | CELLULAR MACROMOLECULE LOCALIZATION | 98 | 1234 | 1.291e-06 | 9.239e-05 |
66 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 113 | 1492 | 1.914e-06 | 0.0001349 |
67 | GASTRULATION | 23 | 155 | 1.968e-06 | 0.0001367 |
68 | FOREBRAIN DEVELOPMENT | 39 | 357 | 2.466e-06 | 0.0001663 |
69 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 71 | 823 | 2.45e-06 | 0.0001663 |
70 | CELL PROJECTION ORGANIZATION | 76 | 902 | 2.596e-06 | 0.0001726 |
71 | POSITIVE REGULATION OF OSSIFICATION | 16 | 84 | 2.668e-06 | 0.0001749 |
72 | NEURON PROJECTION GUIDANCE | 27 | 205 | 2.807e-06 | 0.0001814 |
73 | REGULATION OF VIRAL GENOME REPLICATION | 15 | 75 | 2.882e-06 | 0.0001837 |
74 | NEGATIVE REGULATION OF VIRAL GENOME REPLICATION | 12 | 49 | 3.044e-06 | 0.0001914 |
75 | IMMUNE SYSTEM PROCESS | 141 | 1984 | 3.143e-06 | 0.000195 |
76 | RESPONSE TO GROWTH FACTOR | 47 | 475 | 3.844e-06 | 0.0002353 |
77 | POSITIVE REGULATION OF LOCOMOTION | 43 | 420 | 4.175e-06 | 0.0002523 |
78 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 30 | 247 | 4.345e-06 | 0.0002592 |
79 | REGULATION OF KINASE ACTIVITY | 67 | 776 | 4.604e-06 | 0.0002678 |
80 | CELL JUNCTION ASSEMBLY | 20 | 129 | 4.574e-06 | 0.0002678 |
81 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 17 | 98 | 5.004e-06 | 0.0002806 |
82 | TUBE DEVELOPMENT | 52 | 552 | 4.978e-06 | 0.0002806 |
83 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 52 | 552 | 4.978e-06 | 0.0002806 |
84 | BIOLOGICAL ADHESION | 83 | 1032 | 5.447e-06 | 0.0003017 |
85 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 22 | 153 | 5.527e-06 | 0.0003025 |
86 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 31 | 264 | 6.101e-06 | 0.0003301 |
87 | FORMATION OF PRIMARY GERM LAYER | 18 | 110 | 6.257e-06 | 0.0003347 |
88 | EXTRACELLULAR STRUCTURE ORGANIZATION | 34 | 304 | 6.462e-06 | 0.0003417 |
89 | POSITIVE REGULATION OF CELL COMMUNICATION | 113 | 1532 | 6.553e-06 | 0.0003426 |
90 | REGULATION OF CELL PROJECTION ORGANIZATION | 52 | 558 | 6.767e-06 | 0.0003499 |
91 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 23 | 167 | 7.123e-06 | 0.0003642 |
92 | TELENCEPHALON DEVELOPMENT | 28 | 228 | 7.267e-06 | 0.0003676 |
93 | ESTABLISHMENT OF PROTEIN LOCALIZATION | 106 | 1423 | 8.504e-06 | 0.0004255 |
94 | REGULATION OF PROTEIN LOCALIZATION | 77 | 950 | 9.147e-06 | 0.0004528 |
95 | NEURON DEVELOPMENT | 60 | 687 | 1.028e-05 | 0.0005034 |
96 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 64 | 750 | 1.094e-05 | 0.0005301 |
97 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 111 | 1518 | 1.171e-05 | 0.0005504 |
98 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 81 | 1021 | 1.171e-05 | 0.0005504 |
99 | UROGENITAL SYSTEM DEVELOPMENT | 33 | 299 | 1.162e-05 | 0.0005504 |
100 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 48 | 513 | 1.368e-05 | 0.0006366 |
101 | EPITHELIAL CELL DEVELOPMENT | 24 | 186 | 1.401e-05 | 0.0006453 |
102 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 66 | 788 | 1.45e-05 | 0.0006552 |
103 | CIRCULATORY SYSTEM DEVELOPMENT | 66 | 788 | 1.45e-05 | 0.0006552 |
104 | NEURON PROJECTION DEVELOPMENT | 50 | 545 | 1.547e-05 | 0.000692 |
105 | POSITIVE REGULATION OF CELL DEVELOPMENT | 45 | 472 | 1.586e-05 | 0.0007027 |
106 | MESODERM DEVELOPMENT | 18 | 118 | 1.701e-05 | 0.0007468 |
107 | ORGAN MORPHOGENESIS | 69 | 841 | 1.82e-05 | 0.0007841 |
108 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 102 | 1381 | 1.811e-05 | 0.0007841 |
109 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 87 | 1135 | 2.03e-05 | 0.0008664 |
110 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 21 | 154 | 2.05e-05 | 0.0008673 |
111 | CELL CYCLE PHASE TRANSITION | 29 | 255 | 2.214e-05 | 0.00092 |
112 | ESTABLISHMENT OF CELL POLARITY | 15 | 88 | 2.213e-05 | 0.00092 |
113 | MESODERMAL CELL DIFFERENTIATION | 8 | 26 | 2.273e-05 | 0.0009359 |
114 | REGULATION OF NEURON DIFFERENTIATION | 50 | 554 | 2.387e-05 | 0.0009743 |
115 | NEURON MIGRATION | 17 | 110 | 2.434e-05 | 0.0009847 |
116 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 40 | 408 | 2.465e-05 | 0.0009886 |
117 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 61 | 724 | 2.569e-05 | 0.001022 |
118 | REGULATION OF CELLULAR LOCALIZATION | 95 | 1277 | 2.709e-05 | 0.001063 |
119 | CELLULAR RESPONSE TO STRESS | 112 | 1565 | 2.718e-05 | 0.001063 |
120 | REGULATION OF CELL CYCLE | 75 | 949 | 2.827e-05 | 0.001087 |
121 | POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 12 | 60 | 2.809e-05 | 0.001087 |
122 | INTERACTION WITH HOST | 19 | 134 | 2.889e-05 | 0.001102 |
123 | POSITIVE REGULATION OF CELL DEATH | 53 | 605 | 3.093e-05 | 0.00117 |
124 | PEPTIDYL AMINO ACID MODIFICATION | 68 | 841 | 3.317e-05 | 0.001245 |
125 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 80 | 1036 | 3.428e-05 | 0.001266 |
126 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 80 | 1036 | 3.428e-05 | 0.001266 |
127 | RESPONSE TO MECHANICAL STIMULUS | 25 | 210 | 3.741e-05 | 0.001371 |
128 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 65 | 799 | 4.116e-05 | 0.001485 |
129 | POSITIVE REGULATION OF CELL CYCLE | 34 | 332 | 4.112e-05 | 0.001485 |
130 | ANION TRANSPORT | 46 | 507 | 4.407e-05 | 0.001577 |
131 | REGULATION OF CELLULAR RESPONSE TO STRESS | 58 | 691 | 4.501e-05 | 0.001599 |
132 | EMBRYONIC MORPHOGENESIS | 48 | 539 | 4.834e-05 | 0.00169 |
133 | MITOTIC CELL CYCLE CHECKPOINT | 19 | 139 | 4.84e-05 | 0.00169 |
134 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 36 | 363 | 4.868e-05 | 0.00169 |
135 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 71 | 905 | 5.827e-05 | 0.002005 |
136 | GLAND DEVELOPMENT | 38 | 395 | 5.867e-05 | 0.002005 |
137 | ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 19 | 141 | 5.902e-05 | 0.002005 |
138 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 11 | 55 | 6.028e-05 | 0.002032 |
139 | VASCULATURE DEVELOPMENT | 43 | 469 | 6.093e-05 | 0.00204 |
140 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 36 | 368 | 6.462e-05 | 0.002148 |
141 | MESODERM MORPHOGENESIS | 12 | 66 | 7.543e-05 | 0.002489 |
142 | REGULATION OF TRANSFERASE ACTIVITY | 73 | 946 | 7.746e-05 | 0.002538 |
143 | CIRCADIAN REGULATION OF GENE EXPRESSION | 11 | 57 | 8.499e-05 | 0.002766 |
144 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 71 | 917 | 8.758e-05 | 0.00283 |
145 | RESPONSE TO EXTERNAL STIMULUS | 124 | 1821 | 9.104e-05 | 0.002921 |
146 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 48 | 554 | 9.464e-05 | 0.002991 |
147 | DNA INTEGRITY CHECKPOINT | 19 | 146 | 9.513e-05 | 0.002991 |
148 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 38 | 404 | 9.445e-05 | 0.002991 |
149 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 85 | 1152 | 9.653e-05 | 0.003014 |
150 | CELL CYCLE G1 S PHASE TRANSITION | 16 | 111 | 9.891e-05 | 0.003048 |
151 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 16 | 111 | 9.891e-05 | 0.003048 |
152 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 40 | 437 | 0.0001127 | 0.00345 |
153 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 68 | 876 | 0.0001143 | 0.003476 |
154 | REPRODUCTIVE SYSTEM DEVELOPMENT | 38 | 408 | 0.0001159 | 0.003481 |
155 | REGULATION OF CELL MATRIX ADHESION | 14 | 90 | 0.0001157 | 0.003481 |
156 | RESPONSE TO HORMONE | 69 | 893 | 0.0001169 | 0.003487 |
157 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 23 | 199 | 0.0001186 | 0.003516 |
158 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 13 | 80 | 0.0001278 | 0.003763 |
159 | REGULATION OF COENZYME METABOLIC PROCESS | 10 | 50 | 0.0001297 | 0.003773 |
160 | REGULATION OF COFACTOR METABOLIC PROCESS | 10 | 50 | 0.0001297 | 0.003773 |
161 | STEM CELL PROLIFERATION | 11 | 60 | 0.0001381 | 0.003965 |
162 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 11 | 60 | 0.0001381 | 0.003965 |
163 | REGULATION OF TRANSPORT | 122 | 1804 | 0.000139 | 0.003969 |
164 | LENS FIBER CELL DIFFERENTIATION | 7 | 25 | 0.0001457 | 0.004134 |
165 | SISTER CHROMATID SEGREGATION | 21 | 176 | 0.0001475 | 0.004159 |
166 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 25 | 229 | 0.0001533 | 0.004298 |
167 | MESENCHYME DEVELOPMENT | 22 | 190 | 0.000161 | 0.004461 |
168 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 11 | 61 | 0.0001611 | 0.004461 |
169 | CELLULAR RESPONSE TO HORMONE STIMULUS | 47 | 552 | 0.0001677 | 0.004616 |
170 | REGULATION OF CELL DIVISION | 28 | 272 | 0.0001744 | 0.004773 |
171 | PALLIUM DEVELOPMENT | 19 | 153 | 0.000178 | 0.004842 |
172 | NEURON PROJECTION MORPHOGENESIS | 37 | 402 | 0.0001799 | 0.004867 |
173 | NEUTRAL AMINO ACID TRANSPORT | 8 | 34 | 0.0001864 | 0.005013 |
174 | MORPHOGENESIS OF AN EPITHELIAL SHEET | 9 | 43 | 0.0001947 | 0.005208 |
175 | RESPONSE TO CYTOKINE | 57 | 714 | 0.0001986 | 0.005279 |
176 | REGULATION OF ORGANELLE ORGANIZATION | 85 | 1178 | 0.000203 | 0.005367 |
177 | POSITIVE REGULATION OF CELL ADHESION | 35 | 376 | 0.0002146 | 0.005642 |
178 | HEART DEVELOPMENT | 41 | 466 | 0.0002174 | 0.005682 |
179 | RAS PROTEIN SIGNAL TRANSDUCTION | 18 | 143 | 0.00022 | 0.005718 |
180 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 17 | 131 | 0.0002255 | 0.00583 |
181 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 43 | 498 | 0.000232 | 0.005963 |
182 | CELL CELL JUNCTION ASSEMBLY | 12 | 74 | 0.0002347 | 0.006001 |
183 | CARDIAC SEPTUM DEVELOPMENT | 13 | 85 | 0.000239 | 0.006078 |
184 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 30 | 306 | 0.0002457 | 0.006193 |
185 | BLOOD VESSEL MORPHOGENESIS | 34 | 364 | 0.0002462 | 0.006193 |
186 | CELLULAR COMPONENT MORPHOGENESIS | 68 | 900 | 0.0002492 | 0.006235 |
187 | NEGATIVE REGULATION OF CELL ADHESION | 24 | 223 | 0.0002554 | 0.006339 |
188 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 13 | 0.0002575 | 0.006339 |
189 | REGULATION OF GTPASE ACTIVITY | 54 | 673 | 0.0002562 | 0.006339 |
190 | GROWTH | 37 | 410 | 0.0002654 | 0.006499 |
191 | REGULATION OF CYTOSKELETON ORGANIZATION | 43 | 502 | 0.0002754 | 0.006708 |
192 | REGULATION OF NEURON DEATH | 26 | 252 | 0.0002826 | 0.006848 |
193 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 18 | 146 | 0.0002853 | 0.006879 |
194 | MICROVILLUS ORGANIZATION | 6 | 20 | 0.0002904 | 0.006966 |
195 | RESPONSE TO ABIOTIC STIMULUS | 75 | 1024 | 0.00031 | 0.007397 |
196 | REGULATION OF LIPID METABOLIC PROCESS | 28 | 282 | 0.0003172 | 0.007493 |
197 | REGULATION OF CELL MORPHOGENESIS | 46 | 552 | 0.0003169 | 0.007493 |
198 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 14 | 99 | 0.0003237 | 0.007569 |
199 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 14 | 99 | 0.0003237 | 0.007569 |
200 | SISTER CHROMATID COHESION | 15 | 111 | 0.0003327 | 0.007741 |
201 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 22 | 200 | 0.0003348 | 0.007741 |
202 | REGULATION OF BINDING | 28 | 283 | 0.0003361 | 0.007741 |
203 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 14 | 100 | 0.0003598 | 0.008247 |
204 | ORGANIC ANION TRANSPORT | 35 | 387 | 0.0003693 | 0.008422 |
205 | NEGATIVE REGULATION OF VIRAL PROCESS | 13 | 89 | 0.0003799 | 0.00854 |
206 | EPITHELIAL CELL PROLIFERATION | 13 | 89 | 0.0003799 | 0.00854 |
207 | POST EMBRYONIC DEVELOPMENT | 13 | 89 | 0.0003799 | 0.00854 |
208 | CIRCADIAN RHYTHM | 17 | 137 | 0.0003858 | 0.008589 |
209 | CDP DIACYLGLYCEROL METABOLIC PROCESS | 5 | 14 | 0.0003844 | 0.008589 |
210 | REGULATION OF CELL CYCLE PROCESS | 46 | 558 | 0.0004015 | 0.008897 |
211 | CHROMOSOME SEGREGATION | 27 | 272 | 0.0004042 | 0.008914 |
212 | ENDOMEMBRANE SYSTEM ORGANIZATION | 40 | 465 | 0.0004075 | 0.008944 |
213 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 33 | 360 | 0.0004227 | 0.009227 |
214 | STEM CELL DIFFERENTIATION | 21 | 190 | 0.0004244 | 0.009227 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | RIBONUCLEOTIDE BINDING | 172 | 1860 | 7.815e-17 | 7.26e-14 |
2 | ENZYME BINDING | 157 | 1737 | 1.685e-14 | 7.826e-12 |
3 | MACROMOLECULAR COMPLEX BINDING | 134 | 1399 | 2.622e-14 | 8.12e-12 |
4 | ADENYL NUCLEOTIDE BINDING | 140 | 1514 | 1.007e-13 | 2.338e-11 |
5 | KINASE ACTIVITY | 84 | 842 | 3.761e-10 | 6.146e-08 |
6 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 45 | 328 | 3.969e-10 | 6.146e-08 |
7 | CYTOSKELETAL PROTEIN BINDING | 82 | 819 | 5.193e-10 | 6.26e-08 |
8 | PROTEIN COMPLEX BINDING | 90 | 935 | 5.39e-10 | 6.26e-08 |
9 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 93 | 992 | 1.069e-09 | 1.103e-07 |
10 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 67 | 629 | 1.769e-09 | 1.644e-07 |
11 | REGULATORY REGION NUCLEIC ACID BINDING | 80 | 818 | 2.532e-09 | 2.138e-07 |
12 | DOUBLE STRANDED DNA BINDING | 75 | 764 | 6.955e-09 | 5.385e-07 |
13 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 33 | 226 | 1.868e-08 | 1.335e-06 |
14 | PROTEIN KINASE ACTIVITY | 64 | 640 | 4.645e-08 | 3.082e-06 |
15 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 43 | 371 | 1.489e-07 | 9.221e-06 |
16 | KINASE BINDING | 60 | 606 | 1.741e-07 | 1.011e-05 |
17 | HYDROLASE ACTIVITY ACTING ON ACID ANHYDRIDES | 74 | 820 | 2.704e-07 | 1.478e-05 |
18 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 98 | 1199 | 3.53e-07 | 1.822e-05 |
19 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 37 | 315 | 7.873e-07 | 3.85e-05 |
20 | ACTIN BINDING | 42 | 393 | 1.811e-06 | 8.41e-05 |
21 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 55 | 588 | 3.295e-06 | 0.0001458 |
22 | SEQUENCE SPECIFIC DNA BINDING | 84 | 1037 | 3.622e-06 | 0.000153 |
23 | PROTEIN DOMAIN SPECIFIC BINDING | 57 | 624 | 4.526e-06 | 0.0001828 |
24 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 44 | 445 | 7.93e-06 | 0.0003069 |
25 | IDENTICAL PROTEIN BINDING | 93 | 1209 | 9.025e-06 | 0.0003354 |
26 | GROWTH FACTOR BINDING | 18 | 123 | 3.024e-05 | 0.001081 |
27 | DOUBLE STRANDED RNA BINDING | 12 | 64 | 5.506e-05 | 0.001894 |
28 | COLLAGEN BINDING | 12 | 65 | 6.455e-05 | 0.002142 |
29 | MOTOR ACTIVITY | 18 | 131 | 7.076e-05 | 0.002267 |
30 | TUBULIN BINDING | 29 | 273 | 7.735e-05 | 0.002395 |
31 | GUANYL NUCLEOTIDE BINDING | 37 | 390 | 9.743e-05 | 0.00292 |
32 | NEUTRAL AMINO ACID TRANSMEMBRANE TRANSPORTER ACTIVITY | 8 | 32 | 0.0001178 | 0.003319 |
33 | CELL ADHESION MOLECULE BINDING | 22 | 186 | 0.0001179 | 0.003319 |
34 | PROTEIN KINASE C BINDING | 10 | 50 | 0.0001297 | 0.003444 |
35 | GTPASE BINDING | 30 | 295 | 0.0001293 | 0.003444 |
36 | MOLECULAR FUNCTION REGULATOR | 96 | 1353 | 0.000144 | 0.003717 |
37 | CORE PROMOTER BINDING | 19 | 152 | 0.0001632 | 0.004097 |
38 | INTEGRIN BINDING | 15 | 105 | 0.0001789 | 0.004374 |
39 | GTPASE ACTIVITY | 26 | 246 | 0.0001929 | 0.004481 |
40 | TRANSCRIPTION FACTOR BINDING | 45 | 524 | 0.0001892 | 0.004481 |
41 | CHROMATIN BINDING | 39 | 435 | 0.0002096 | 0.004749 |
42 | RAB GTPASE BINDING | 16 | 120 | 0.0002497 | 0.005522 |
43 | DNA BINDING BENDING | 6 | 20 | 0.0002904 | 0.006275 |
44 | MICROFILAMENT MOTOR ACTIVITY | 6 | 21 | 0.0003899 | 0.008231 |
45 | GLYCOPROTEIN BINDING | 14 | 101 | 0.0003992 | 0.008242 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ANCHORING JUNCTION | 63 | 489 | 1.994e-12 | 7.911e-10 |
2 | CELL LEADING EDGE | 51 | 350 | 2.709e-12 | 7.911e-10 |
3 | CELL SUBSTRATE JUNCTION | 54 | 398 | 1.063e-11 | 2.07e-09 |
4 | CELL JUNCTION | 109 | 1151 | 1.834e-11 | 2.678e-09 |
5 | CELL CELL JUNCTION | 50 | 383 | 2.498e-10 | 2.918e-08 |
6 | CYTOSKELETON | 152 | 1967 | 6.277e-09 | 6.11e-07 |
7 | NEURON PROJECTION | 84 | 942 | 6.871e-08 | 5.733e-06 |
8 | MEMBRANE REGION | 96 | 1134 | 9.304e-08 | 6.792e-06 |
9 | ACTIN CYTOSKELETON | 48 | 444 | 2.383e-07 | 1.392e-05 |
10 | GOLGI APPARATUS | 114 | 1445 | 2.265e-07 | 1.392e-05 |
11 | PLASMA MEMBRANE REGION | 81 | 929 | 3.036e-07 | 1.612e-05 |
12 | APICAL JUNCTION COMPLEX | 21 | 128 | 1.036e-06 | 5.044e-05 |
13 | CELL PROJECTION | 131 | 1786 | 1.474e-06 | 6.624e-05 |
14 | RUFFLE | 23 | 156 | 2.203e-06 | 8.725e-05 |
15 | ENDOPLASMIC RETICULUM | 121 | 1631 | 2.241e-06 | 8.725e-05 |
16 | CYTOSKELETAL PART | 109 | 1436 | 2.675e-06 | 9.765e-05 |
17 | CHROMOSOME | 73 | 880 | 7.105e-06 | 0.0002441 |
18 | LEADING EDGE MEMBRANE | 20 | 134 | 8.253e-06 | 0.0002677 |
19 | PROTEIN COMPLEX INVOLVED IN CELL ADHESION | 9 | 30 | 8.764e-06 | 0.0002694 |
20 | LAMELLIPODIUM | 22 | 172 | 3.611e-05 | 0.001054 |
21 | PRONUCLEUS | 6 | 15 | 4.631e-05 | 0.001288 |
22 | NEURON PART | 93 | 1265 | 5.142e-05 | 0.001318 |
23 | DENDRITE | 42 | 451 | 5.19e-05 | 0.001318 |
24 | CELL CELL CONTACT ZONE | 12 | 64 | 5.506e-05 | 0.00134 |
25 | RECYCLING ENDOSOME | 18 | 131 | 7.076e-05 | 0.001653 |
26 | AXON | 39 | 418 | 9.129e-05 | 0.002051 |
27 | SOMATODENDRITIC COMPARTMENT | 54 | 650 | 0.0001069 | 0.002311 |
28 | GOLGI APPARATUS PART | 69 | 893 | 0.0001169 | 0.002439 |
29 | CELL PROJECTION PART | 72 | 946 | 0.0001322 | 0.002662 |
30 | ACTOMYOSIN | 11 | 62 | 0.0001873 | 0.003528 |
31 | INTRACELLULAR VESICLE | 90 | 1259 | 0.0001815 | 0.003528 |
32 | CONDENSED CHROMOSOME | 22 | 195 | 0.000234 | 0.004271 |
33 | CELL CELL ADHERENS JUNCTION | 10 | 54 | 0.0002531 | 0.00448 |
34 | CELL SURFACE | 59 | 757 | 0.000289 | 0.004963 |
35 | ENDOPLASMIC RETICULUM PART | 83 | 1163 | 0.0003412 | 0.005694 |
36 | RECEPTOR COMPLEX | 31 | 327 | 0.0003518 | 0.005706 |
37 | SITE OF POLARIZED GROWTH | 18 | 149 | 0.000367 | 0.005793 |
38 | MICROTUBULE CYTOSKELETON | 77 | 1068 | 0.0004137 | 0.006195 |
39 | SUPRAMOLECULAR FIBER | 53 | 670 | 0.0004092 | 0.006195 |
40 | TRANS GOLGI NETWORK | 21 | 193 | 0.0005232 | 0.007639 |
41 | CHROMATIN | 38 | 441 | 0.0005444 | 0.007754 |
42 | FILOPODIUM | 13 | 94 | 0.00065 | 0.009038 |
43 | BASOLATERAL PLASMA MEMBRANE | 22 | 211 | 0.0006984 | 0.009486 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Cell_cycle_hsa04110 | 27 | 124 | 4.481e-11 | 2.33e-09 | |
2 | PI3K_Akt_signaling_pathway_hsa04151 | 42 | 352 | 9.257e-08 | 2.407e-06 | |
3 | MAPK_signaling_pathway_hsa04010 | 35 | 295 | 1.231e-06 | 2.134e-05 | |
4 | ErbB_signaling_pathway_hsa04012 | 16 | 85 | 3.139e-06 | 4.081e-05 | |
5 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 19 | 139 | 4.84e-05 | 0.0005033 | |
6 | FoxO_signaling_pathway_hsa04068 | 18 | 132 | 7.826e-05 | 0.0005684 | |
7 | AMPK_signaling_pathway_hsa04152 | 17 | 121 | 8.411e-05 | 0.0005684 | |
8 | Regulation_of_actin_cytoskeleton_hsa04810 | 24 | 208 | 8.744e-05 | 0.0005684 | |
9 | Ras_signaling_pathway_hsa04014 | 25 | 232 | 0.0001881 | 0.001087 | |
10 | Cellular_senescence_hsa04218 | 19 | 160 | 0.0003183 | 0.001655 | |
11 | Hippo_signaling_pathway_hsa04390 | 18 | 154 | 0.0005483 | 0.002592 | |
12 | HIF_1_signaling_pathway_hsa04066 | 13 | 100 | 0.001172 | 0.005079 | |
13 | p53_signaling_pathway_hsa04115 | 10 | 68 | 0.001659 | 0.006634 | |
14 | Focal_adhesion_hsa04510 | 20 | 199 | 0.001866 | 0.006931 | |
15 | Endocytosis_hsa04144 | 23 | 244 | 0.002077 | 0.007202 | |
16 | TGF_beta_signaling_pathway_hsa04350 | 11 | 84 | 0.002577 | 0.008374 | |
17 | Rap1_signaling_pathway_hsa04015 | 20 | 206 | 0.002801 | 0.008567 | |
18 | Tight_junction_hsa04530 | 17 | 170 | 0.004153 | 0.012 | |
19 | ECM_receptor_interaction_hsa04512 | 10 | 82 | 0.006611 | 0.01809 | |
20 | Apelin_signaling_pathway_hsa04371 | 14 | 137 | 0.00731 | 0.01901 | |
21 | Adherens_junction_hsa04520 | 9 | 72 | 0.008314 | 0.02059 | |
22 | Hippo_signaling_pathway_multiple_species_hsa04392 | 5 | 29 | 0.0124 | 0.02818 | |
23 | Phospholipase_D_signaling_pathway_hsa04072 | 14 | 146 | 0.01246 | 0.02818 | |
24 | mTOR_signaling_pathway_hsa04150 | 14 | 151 | 0.01635 | 0.03542 | |
25 | Apoptosis_hsa04210 | 13 | 138 | 0.01794 | 0.03704 | |
26 | Oocyte_meiosis_hsa04114 | 12 | 124 | 0.01852 | 0.03704 | |
27 | Hedgehog_signaling_pathway_hsa04340 | 6 | 47 | 0.02627 | 0.05059 | |
28 | Gap_junction_hsa04540 | 9 | 88 | 0.0281 | 0.05219 | |
29 | TNF_signaling_pathway_hsa04668 | 10 | 108 | 0.03889 | 0.06772 | |
30 | Mitophagy_animal_hsa04137 | 7 | 65 | 0.03907 | 0.06772 | |
31 | Cytokine_cytokine_receptor_interaction_hsa04060 | 19 | 270 | 0.07228 | 0.1212 | |
32 | Autophagy_animal_hsa04140 | 10 | 128 | 0.09737 | 0.1582 | |
33 | Phagosome_hsa04145 | 11 | 152 | 0.1264 | 0.1992 | |
34 | Ferroptosis_hsa04216 | 4 | 40 | 0.1305 | 0.1996 | |
35 | Jak_STAT_signaling_pathway_hsa04630 | 11 | 162 | 0.1712 | 0.2544 | |
36 | Wnt_signaling_pathway_hsa04310 | 10 | 146 | 0.179 | 0.2544 | |
37 | Necroptosis_hsa04217 | 11 | 164 | 0.181 | 0.2544 | |
38 | Phosphatidylinositol_signaling_system_hsa04070 | 7 | 99 | 0.2111 | 0.2888 | |
39 | VEGF_signaling_pathway_hsa04370 | 4 | 59 | 0.327 | 0.436 | |
40 | Sphingolipid_signaling_pathway_hsa04071 | 7 | 118 | 0.3567 | 0.4637 | |
41 | cAMP_signaling_pathway_hsa04024 | 11 | 198 | 0.3773 | 0.4785 | |
42 | cGMP_PKG_signaling_pathway_hsa04022 | 9 | 163 | 0.4044 | 0.5006 | |
43 | NF_kappa_B_signaling_pathway_hsa04064 | 5 | 95 | 0.4995 | 0.604 | |
44 | Cell_adhesion_molecules_.CAMs._hsa04514 | 7 | 145 | 0.5694 | 0.6729 | |
45 | Lysosome_hsa04142 | 5 | 123 | 0.7253 | 0.8381 | |
46 | Calcium_signaling_pathway_hsa04020 | 6 | 182 | 0.8859 | 0.9506 | |
47 | Neuroactive_ligand_receptor_interaction_hsa04080 | 6 | 278 | 0.994 | 1 |